Harrison.ai, a Haymarket, Australia-based world healthtech firm and developer of AI-powered medical diagnostic help and workflow options, raised US$112M in Collection C funding.
The spherical, which introduced the whole quantity to $240M, was led by Conscious Tremendous, ECP and current investor Horizons Ventures. New traders, resembling Australia’s Nationwide Reconstruction Fund Company (NRFC), Ord Minnett and Wollemi Capital Group additionally participated, together with current traders together with Blackbird Ventures and Alpha JWC Ventures.
The corporate intends to make use of the funds to increase its U.S. operations and develop its buyer base.
Led by CEO Dr. Aengus Tran, Harrison develops radiology (Annalise.ai) and pathology (Franklin.ai) expertise options that help clinicians with figuring out indicators of most cancers and different crucial sicknesses earlier, bettering therapy selections and affected person outcomes. It makes use of AI to investigate CT scans, X-rays, and pathology slides, supporting clinicians in detecting and diagnosing medical situations sooner and extra precisely.
The corporate companions with hospitals and personal clinics throughout APAC, EMEA, the UK and United States. Additional accelerating its world commercialization efforts, Harrison.ai is establishing a North American presence in Boston specializing in constructing its U.S. operations and rising the shopper base.
Harrison.ai has already acquired 12 FDA clearances, and certainly one of its CT Mind algorithms has FDA Breakthrough System Designation and Medicare reimbursement via the New Know-how Add-on Cost (NTAP).
FinSMEs
11/02/2025
